Measurement of disease activity and outcome in atopic dermatitis.
about
The objective severity assessment of atopic dermatitis (OSAAD) score: validity, reliability and sensitivity in adult patients with atopic dermatitisCutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrumentClinical outcome measures for cutaneous lupus erythematosus.Treatment of cutaneous lupus.Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study.A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczema.Efficacy of korean red ginseng in the treatment of atopic dermatitis.The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measuresDevelopment of outcome measures for autoimmune dermatoses.Reliability and convergent validity of the cutaneous sarcoidosis activity and morphology instrument for assessing cutaneous sarcoidosis.The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus.Reliance on erythema scores may mask severe atopic dermatitis in black children compared with their white counterparts.Assessment of atopic eczema: clinical scoring and noninvasive measurements.The hand eczema severity index (HECSI): a scoring system for clinical assessment of hand eczema. A study of inter- and intraobserver reliability.Determining the severity of atopic dermatitis in children presenting in general practice: an easy and fast method.Measurement of disease severity in cutaneous autoimmune diseases.Differences in efficacy between intention-to-treat and per-protocol analyses for patients with psoriasis vulgaris and atopic dermatitis: clinical and pharmacoeconomic implications.Itch characteristics in Chinese patients with atopic dermatitis using a new questionnaire for the assessment of pruritus.Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme.Use of pimecrolimus cream 1% (Elidel) in the treatment of atopic dermatitis in infants and children: the effects of ethnic origin and baseline disease severity on treatment outcome.The unfavorable effects of concomitant asthma and sleeplessness due to the atopic eczema/dermatitis syndrome (AEDS) on quality of life in subjects allergic to house-dust mites.Prevalence and predictors of psychosocial morbidity in patients with chronic pruritic skin diseases.The effect of dermatology consultations in secondary care on treatment outcome and quality of life in new adult patients with atopic dermatitis.Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score.
P2860
Q28273743-79FF8F1F-C0B9-4E6A-8B26-111A367C7388Q34561606-B1DD01F5-95B9-4359-93DF-69A890651BA2Q34844623-39915DAD-2409-48BF-8E90-1176C420BACAQ35633324-DA0D5238-B301-4D7C-8C96-6F4591967235Q36401559-0F2030DE-756C-4A8A-BA7E-EB66DAD7DEA0Q36480608-3C682960-68D6-4360-9758-6134DE5E3A24Q36860868-D9DF3133-A550-4B72-901C-8BDE4BAF5680Q36949289-2CBDA44A-AE56-43D0-AB61-E6C1E4C99990Q36994240-B1674F47-AF72-4307-9D50-4E2D906EF828Q37404210-6B8F6A8C-4954-4256-B9C5-A3A074641630Q37591255-D58CA681-4F8E-49FC-99DB-3B7B2FC06CC5Q39634858-7684AEDA-047E-4F7A-86F2-194724F856CCQ40187221-F35C885F-DC1F-4881-8D57-69DDAC710C47Q40443395-6DDF930E-24B6-4666-B5CF-BEAB519557F7Q40852027-30AE0E97-D1CF-40F2-98F2-C53FE3F77552Q41558860-84CB015D-2EEE-44CC-89C9-34E4ED13B91EQ43650487-3B5D21A2-A534-44A6-B5BF-55046B365DB5Q44148036-D47D9F6E-6E74-4893-8FFB-986903AB875CQ44744546-B0204990-52E8-456A-ACED-1B9308366174Q45233158-DC82837C-024D-4BA0-81E5-F035D5D4DF79Q48650274-0FD641B6-1116-4C04-8995-460C4D6185ADQ51913886-B5BCCAAC-0C45-4ACC-B630-BE8C7FA3D14CQ52855859-3FA2F86E-F86C-4B55-B9EA-DBF4C5644C81Q52940578-8889F4EE-595E-40EC-AA25-24A9513EEC0C
P2860
Measurement of disease activity and outcome in atopic dermatitis.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Measurement of disease activity and outcome in atopic dermatitis.
@en
type
label
Measurement of disease activity and outcome in atopic dermatitis.
@en
prefLabel
Measurement of disease activity and outcome in atopic dermatitis.
@en
P1476
Measurement of disease activity and outcome in atopic dermatitis.
@en
P304
P356
10.1046/J.1365-2133.1996.D01-1031.X
P407
P577
1996-10-01T00:00:00Z